Nebula Research & Development LLC Buys 3,700 Shares of STAAR Surgical (NASDAQ:STAA)

Nebula Research & Development LLC grew its stake in STAAR Surgical (NASDAQ:STAA) by 19.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,210 shares of the medical instruments supplier’s stock after acquiring an additional 3,700 shares during the period. Nebula Research & Development LLC’s holdings in STAAR Surgical were worth $564,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of STAA. KLP Kapitalforvaltning AS acquired a new position in STAAR Surgical during the fourth quarter valued at approximately $180,000. Quantbot Technologies LP acquired a new stake in shares of STAAR Surgical in the 4th quarter valued at about $278,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of STAAR Surgical in the fourth quarter valued at about $292,000. Counterpoint Mutual Funds LLC acquired a new stake in shares of STAAR Surgical in the fourth quarter valued at about $298,000. Finally, HighTower Advisors LLC boosted its holdings in shares of STAAR Surgical by 42.6% during the fourth quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier’s stock worth $315,000 after acquiring an additional 3,871 shares during the period. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analysts Set New Price Targets

STAA has been the subject of a number of research analyst reports. Stifel Nicolaus reduced their price objective on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. Wells Fargo & Company initiated coverage on STAAR Surgical in a report on Monday, April 21st. They set an “equal weight” rating and a $17.00 price objective for the company. Jefferies Financial Group cut STAAR Surgical from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. Finally, Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday, March 18th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $24.25.

STAAR Surgical Stock Up 0.7 %

NASDAQ:STAA opened at $18.16 on Tuesday. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $49.86. The stock’s 50-day simple moving average is $17.23 and its 200 day simple moving average is $22.63. The firm has a market capitalization of $895.74 million, a PE ratio of -44.29 and a beta of 0.75.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 108,720 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were purchased at an average price of $17.96 per share, for a total transaction of $1,952,611.20. Following the completion of the transaction, the insider now directly owns 12,182,995 shares in the company, valued at approximately $218,806,590.20. The trade was a 0.90 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders have acquired a total of 1,742,581 shares of company stock worth $28,407,543 over the last 90 days. Insiders own 1.00% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.